Home/ Stocks/ RNXT

RenovoRx, Inc. Common Stock

RNXT XNAS

$1.12 -0.03 (-2.61%) ▼ 15-min delayed

Open

$1.17

High

$1.20

Low

$1.10

Volume

317.8K

Market Cap

$51.86M

About RenovoRx, Inc. Common Stock

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$563.0K	$-3,521,000	$-0.09
FY 2025	$1.12M	$-11,168,000	$-0.32
Q3 2025	$213.0K	$-2,912,000	$-0.08
Q2 2025	$270.0K	$-2,895,000	$-0.08

Related Market News

No specific coverage for RNXT yet. Check out our latest market news or earnings calendar.

Get RNXT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on RenovoRx, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.